IMO-2055

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
IMO-2055
Accession Number
DB06181
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
External IDs
EMD-1201081 / HYB-2055 / HYB2055 / IMO-2055
International/Other Brands
IMOxine
Categories
UNII
8566421Q5R
CAS number
847484-35-9
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in renal cell carcinoma, solid tumors, and lung cancer.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentColorectal Cancers1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:16 / Updated on June 04, 2019 06:21